Trial Profile

A randomized, double-blind, placebo-controlled Phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetics of MK-8507 and potential for drug-drug interaction with midazolam in healthy adult participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2021 Status has been changed to completed, as per Results published in the Antimicrobial Agents and Chemotherapy
13 Sep 2021 Results from MK- 8507-001 and MK- 8507-002, analysing pharmacokinetic and safety of MK-8507, published in the Antimicrobial Agents and Chemotherapy
15 Oct 2020 Results presented in a Merck & Co Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com